The globalization of domestically produced medical aesthetic devices is accelerating. On May 28, Eastern Time, ZenTite (Peninsula Counterclockwise) by Shenzhen Peninsula Medical Group Co., Ltd. (hereinafter referred to as “Peninsula Medical”) was installed at the Wellman Center for Photomedicine in Boston. The Wellman Center for Photomedicine is affiliated with Massachusetts General Hospital, Harvard Medical School, and primarily focuses on researching the effects of light on human biology and developing light-mediated minimally invasive diagnostic and therapeutic technologies. The installation at this influential U.S. medical institution is a result of Peninsula Medical’s technological breakthroughs, certification barrier crossings, and globalization strategy.
As the fifth-generation golden microneedling device independently developed and produced by Peninsula Medical, ZenTite targets refined treatments for the face, eyes, and neck. It addresses the issue of intense pain associated with traditional golden microneedling devices, offers more precise treatment depth, achieves layered dermal therapy, and meets consumers’ personalized treatment needs. Earlier this year, ZenTite obtained the FDA 510(k) registration certificate, making it the first radiofrequency microneedling device in China to receive this certification, laying the foundation for entry into the North American market. In addition to the Wellman Center for Photomedicine, ZenTite has been installed at Maryland Dermatology Laser, Skin & Vein Institute, Scripps Health Center, Bass Plastic Surgery Clinic, and Metropolitan Skin Clinic in the United States. Peninsula Medical plans to continue promoting the registration of other devices in overseas markets. “Previously, our overseas market entry primarily involved home-use products, such as hair growth caps. This year, we obtained the first FDA 510(k) registration certificate for a ‘large device,’ marking the beginning of steady progress. We are currently synchronizing the registration of other large devices and building our overseas team,” Peninsula Medical stated to SignalWind. This will also provide more growth opportunities for Peninsula Medical’s overseas revenue. According to Grand View Research data, the North American energy-based medical aesthetic device market dominates globally, accounting for nearly 40% of revenue share in 2023. The successful entry of Peninsula Medical’s independently developed devices into the U.S. market represents a significant breakthrough for domestically produced energy-based medical aesthetic devices. On one hand, domestic companies previously relied on acquiring overseas brands to enter the international market. For example, Fosun Pharma’s Sisram Medical (1696.HK) acquired Israel’s Alma Lasers, a top-five global energy-based medical aesthetic device company, while Haohai Biological Technology (688366.SH) entered the field by acquiring the Israeli radiofrequency brand EndyMe.On the other hand, from an industry perspective, the global energy-based medical aesthetic device market—including products such as microneedling RF systems—has long been dominated by international brands like Lumenis. In contrast, leading domestic aesthetic companies such as Imeik Technology (300896.SZ) have focused primarily on injectable products, with limited involvement in energy-based medical aesthetic equipment.
However, this segment holds considerable market potential. According to third-party agency Global Market Insights, the global energy-based medical aesthetic device market is projected to grow from $5.6 billion in 2025 to $24.9 billion by 2034, achieving a compound annual growth rate (CAGR) of 17.9%. The entry of Peninsula Counterclockwise into multiple medical institutions in North America marks a new breakthrough in the globalization of domestically produced energy-based equipment. Risk Warning and Disclaimer: The market carries risks, and investments should be made cautiously. This article does not constitute personal investment advice, nor does it consider individual users’ specific investment objectives, financial situations, or needs. Users should evaluate whether any opinions, views, or conclusions herein align with their particular circumstances. Investments made based on this information are undertaken at one’s own responsibility.
